1. Home
  2. PAI vs CGEN Comparison

PAI vs CGEN Comparison

Compare PAI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Investment Grade Income Fund Inc.

PAI

Western Asset Investment Grade Income Fund Inc.

HOLD

Current Price

$12.36

Market Cap

118.3M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.54

Market Cap

125.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAI
CGEN
Founded
1973
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.3M
125.3M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
PAI
CGEN
Price
$12.36
$1.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.0K
285.4K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
4.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,903,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$231.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.59
$1.13
52 Week High
$12.63
$2.66

Technical Indicators

Market Signals
Indicator
PAI
CGEN
Relative Strength Index (RSI) 39.97 41.58
Support Level $12.36 $1.47
Resistance Level $12.44 $1.72
Average True Range (ATR) 0.08 0.09
MACD 0.01 0.00
Stochastic Oscillator 19.05 12.00

Price Performance

Historical Comparison
PAI
CGEN

About PAI Western Asset Investment Grade Income Fund Inc.

Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: